Medco, Boehringer Mannheim Pharmaceuticals Corp. deal

MRE reacquired the worldwide manufacturing and marketing rights to BiDil, a combination formulation of hydralazine hydrochloride and isosorbide dinitrate for congestive heart failure, from Boehringer Mannheim. The companies agreed last April to terminate their November 1993 agreement as Boehringer focused on other products. MRE will retain $350,000 of the $1 million license fee, which will be considered income for the second quarter or 1996. The company plans to look for another partner. ...